STEADYMED LTD.
STDY evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Lead Asset:
- trevyent (BLA Filed)
What it means
What to watch
Prepared research question
What matters most for STDY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
trevyent (BLA Filed)
Next Catalyst
—
Tracking 1 pipeline candidate for STEADYMED LTD..
Run STEADYMED LTD. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available STEADYMED LTD. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: BLA Filed
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is STEADYMED LTD.'s lead drug candidate?
STEADYMED LTD.'s most advanced tracked candidate is trevyent (BLA Filed) for pulmonary arterial hypertension.
Who is the CEO of STEADYMED LTD.?
Jonathan Rigby is the chief executive officer of STEADYMED LTD. (STDY).
What therapeutic areas does STEADYMED LTD. focus on?
STEADYMED LTD. develops therapies across Cardiovascular, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.